Jeffrey Wolf is the founder of Elusys and the Chairman and CEO of Elusys Holdings. He also founded Seed-One Ventures, a firm focused on the systematic formation and management of new biomedical companies founded on breakthrough technology platforms.

Throughout his career, Mr. Wolf specialized in building new life-science companies from the ground-up and plays an active role in managing and supporting the growth of his companies. Mr. Wolf’s start-ups include Avigen (co-founder and director), a NASDAQ gene therapy company; TyRx Pharma (co-founder and chairman), which was focused on the development of novel biocompatible polymers and acquired by Medtronic; and NightHawk Biosciences (founder), a NASDAQ biomedical company focused on oncology, biodefense and the manufacture of large molecule biologics for clinical and commercial development.

Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law, and his B.A. from the University of Chicago where he graduated with honors in economics.